Cargando…

Receptor-binding domain-based subunit vaccines against MERS-CoV

Development of effective vaccines, in particular, subunit-based vaccines, against emerging Middle East respiratory syndrome (MERS) caused by the MERS coronavirus (MERS-CoV) will provide the safest means of preventing the continuous spread of MERS in humans and camels. This review briefly describes t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Naru, Tang, Jian, Lu, Lu, Jiang, Shibo, Du, Lanying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439384/ https://www.ncbi.nlm.nih.gov/pubmed/25445336 http://dx.doi.org/10.1016/j.virusres.2014.11.013

Ejemplares similares

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
por: Zhang, Naru, et al.
Publicado: (2016)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
por: Zhao, Guangyu, et al.
Publicado: (2018)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2016)

Advances in mRNA and other vaccines against MERS-CoV
por: Tai, Wanbo, et al.
Publicado: (2022)

Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread
por: Lu, Lu, et al.
Publicado: (2013)

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
por: Wang, Ning, et al.
Publicado: (2020)

MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
por: Tai, Wanbo, et al.
Publicado: (2023)

The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development
por: Zhou, Nan, et al.
Publicado: (2014)

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
por: Tai, Wanbo, et al.
Publicado: (2020)

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines
por: Jiang, Shibo, et al.
Publicado: (2012)

Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4
por: Jiang, Shibo, et al.
Publicado: (2013)

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD
por: Wang, Cong, et al.
Publicado: (2019)

Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients
por: Cao, Zhiliang, et al.
Publicado: (2010)

A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC
por: Jiang, Shibo, et al.
Publicado: (2013)

Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen
por: Lan, Jiaming, et al.
Publicado: (2014)

Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells
por: Du, Lanying, et al.
Publicado: (2009)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection
por: Channappanavar, Rudragouda, et al.
Publicado: (2015)

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
por: Li, Yan, et al.
Publicado: (2015)

Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
por: Du, Lanying, et al.
Publicado: (2007)

Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines
por: Du, Lanying, et al.
Publicado: (2016)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
por: He, Lei, et al.
Publicado: (2019)

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine
por: He, Yuxian, et al.
Publicado: (2004)

Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
por: Okba, Nisreen M. A., et al.
Publicado: (2020)

Development of Small-Molecule MERS-CoV Inhibitors
por: Liang, Ruiying, et al.
Publicado: (2018)

The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation
por: George, Parakkal Jovvian, et al.
Publicado: (2020)

Glycosylated Delta-receptor-binding domain mucosal vaccine elicits broadly neutralizing antibodies with protection against SARS-CoV-2 challenge
por: Guan, Xiaoqing, et al.
Publicado: (2023)

Crystallization and Structural Determination of the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein
por: Zhou, Haixia, et al.
Publicado: (2019)

Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
por: Jiang, Shibo, et al.
Publicado: (2015)

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
por: Yuan, Yuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dqhd32d0k0hta3jme337e9opmn